Centessa Pharmaceuticals (CNTA) said late Thursday it priced an underwritten public offering of about 15.3 million American depositary shares at $14.75 per ADS for expected gross proceeds of about $225 million.
Each ADS represents one ordinary share. The offering was upsized from $150 million.
Underwriters have been granted a 30-day option to buy up to about 2.3 million additional ADSs.
The offering is set to close around Sept. 16.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments